Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Equity Average: 2011-2025

Historic Equity Average for Ironwood Pharmaceuticals (IRWD) over the last 14 years, with Sep 2025 value amounting to -$286.2 million.

  • Ironwood Pharmaceuticals' Equity Average rose 9.59% to -$286.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$286.2 million, marking a year-over-year increase of 9.59%. This contributed to the annual value of -$323.8 million for FY2024, which is 311.59% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Equity Average stood at -$286.2 million, which was up 10.88% from -$321.1 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Equity Average's 5-year high stood at $679.6 million during Q1 2023, with a 5-year trough of -$338.4 million in Q1 2024.
  • Moreover, its 3-year median value for Equity Average was -$317.7 million (2025), whereas its average is -$184.1 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Equity Average skyrocketed by 3,627.52% in 2021 and then plummeted by 281.14% in 2024.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Equity Average stood at $592.9 million in 2021, then increased by 4.86% to $621.7 million in 2022, then plummeted by 154.04% to -$336.0 million in 2023, then climbed by 8.83% to -$306.3 million in 2024, then rose by 9.59% to -$286.2 million in 2025.
  • Its Equity Average stands at -$286.2 million for Q3 2025, versus -$321.1 million for Q2 2025 and -$317.7 million for Q1 2025.